CU20180159A7 - DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS - Google Patents

DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS

Info

Publication number
CU20180159A7
CU20180159A7 CU2018000159A CU20180159A CU20180159A7 CU 20180159 A7 CU20180159 A7 CU 20180159A7 CU 2018000159 A CU2018000159 A CU 2018000159A CU 20180159 A CU20180159 A CU 20180159A CU 20180159 A7 CU20180159 A7 CU 20180159A7
Authority
CU
Cuba
Prior art keywords
bordetella pertussis
synthetic
oligosaccharids
derivatives
vaccine against
Prior art date
Application number
CU2018000159A
Other languages
Spanish (es)
Inventor
Guangwu Chen
Guo Lina
Fenández Castillo Sonsire
Guillermo Vérez Bencomo Vicente
Original Assignee
Chengdu Olisynn Biotechnology Co Ltd
Inst Finlay De Vacunas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Olisynn Biotechnology Co Ltd, Inst Finlay De Vacunas filed Critical Chengdu Olisynn Biotechnology Co Ltd
Priority to CU2018000159A priority Critical patent/CU20180159A7/en
Priority to CN201980000706.9A priority patent/CN111819184B/en
Priority to PCT/CU2019/050001 priority patent/WO2020135898A1/en
Publication of CU20180159A7 publication Critical patent/CU20180159A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

<p>La presente invención proporciona fragmentos de oligosacáridos sintéticos provenientes del pentasacárido terminal del lipooligosacárido de Bordetella pertussis, un método para obtener los fragmentos de oligosacáridos sintéticos y los conjugados a partir de los mismos. También proporciona las composiciones vacunales que contienen tales glicoconjugados y que inducen una respuesta inmune capaz de reducir la colonización nasofaríngea de Bordetella pertussis.</p><p> The present invention provides synthetic oligosaccharide fragments derived from the terminal pentasaccharide of the Bordetella pertussis lipooligosaccharide, a method for obtaining the synthetic oligosaccharide fragments and the conjugates therefrom. It also provides the vaccine compositions that contain such glycoconjugates and that induce an immune response capable of reducing the nasopharyngeal colonization of Bordetella pertussis. </p>

CU2018000159A 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS CU20180159A7 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CU2018000159A CU20180159A7 (en) 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS
CN201980000706.9A CN111819184B (en) 2018-12-28 2019-04-08 Synthetic oligosaccharide derivatives as vaccines against Bordetella pertussis
PCT/CU2019/050001 WO2020135898A1 (en) 2018-12-28 2019-04-08 Synthetic oligosaccharide derivatives as a vaccine against bordetella pertussis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2018000159A CU20180159A7 (en) 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS

Publications (1)

Publication Number Publication Date
CU20180159A7 true CU20180159A7 (en) 2020-10-20

Family

ID=66793711

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000159A CU20180159A7 (en) 2018-12-28 2018-12-28 DERIVATIVES OF SYNTHETIC OLIGOSACCHARIDS AS VACCINE AGAINST BORDETELLA PERTUSSIS

Country Status (3)

Country Link
CN (1) CN111819184B (en)
CU (1) CU20180159A7 (en)
WO (1) WO2020135898A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200671A (en) * 2000-06-02 2004-08-16 Pfizer Products Inc. Hygromycin A derivatives for the treatment of bacterial and protozoal infections
WO2012106251A2 (en) * 2011-01-31 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pertussis vaccine
PL404247A1 (en) * 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością LOS oligosugar Bordetella pertussis and pertussis toxin and its use in the prevention and treatment of infections caused by Bordetella pertussis
EP3242883A4 (en) * 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
CN108025053A (en) * 2015-04-16 2018-05-11 创赏有限公司 The vaccine combination of Assessment of B. Pertussis Immunogen

Also Published As

Publication number Publication date
CN111819184B (en) 2024-01-12
CN111819184A (en) 2020-10-23
WO2020135898A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
AR125320A2 (en) CRYSTALLINE COMPOUND, METHOD OF PREPARATION AND COMPOSITION INCLUDING IT
MX2021006697A (en) Hair growth composition and method.
MX2017014127A (en) CONTEUGADOS PROTEINA-POLISACARIDO DE ESTREPTOCOCO GROUP B, METHODS TO PRODUCE CONJUGATES, IMMUNOGEN COMPOSITIONS THAT INCLUDE CONJUGATES AND THEIR USES.
CR20200082A (en) IMMUNOGENIC CHIKUNGUNYA VIRUS
BR112021012037A2 (en) Bifunctional anti-pd-1/il-7 molecule
MX391171B (en) High-Affinity Human Anti-CD19 Antibodies
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MX386692B (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
MX362259B (en) Sweet flavor modifier.
MX373361B (en) IMMUNOLOGICAL COMPOSITIONS CONTAINING ATTENUATED HISTOPHILUS SOMNI.
BR112019003577A2 (en) seed treatment methods and resulting products
EA201990010A1 (en) INFECTIOUS Bronchitis Virus Vaccine
AR105010A1 (en) IMMUNOGEN COMPOSITIONS
MX2019009606A (en) Bis-compounds for optically active devices.
MX2016016746A (en) Dual adjuvant vaccine compositions, preparation and uses.
BR112019003992A2 (en) neisseria meningitidis vaccine
UA116697C2 (en) COMPOSITION FOR PREVENTING MYCOPLASMA SPECIES
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
MX385910B (en) FRAGRANCE COMPOSITIONS COMPRISING ETHYL CYCLOHEXANOATE.
CL2018000253A1 (en) Enhanced immune response of swine species
BR112017028224A2 (en) composition, and method for protecting a piglet against a pestivirus-associated disease.
BR112022011945A2 (en) BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT
CL2018000155A1 (en) Liposomal adjuvant compositions
BR112018074910A2 (en) immunological composition, and method of inducing an immune response against equine influenza virus in a subject